Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience

被引：4
|
作者：
Lachenal, Florence [1 ]
Lebreton, Pierre [2 ]
Bouillie, Sylvie [3 ]
Matteo, Gian [4 ]
Aftisse, Hassina [5 ]
Pascal, Laurent [6 ]
Montes, Lydia [7 ]
Macro, Margaret [8 ]
Vignon, Marguerite [9 ]
Harel, Stephanie [10 ]
Fernandez, Mariana [11 ]
Louni, Chanaz [12 ]
Huart, Antoine [13 ]
Perrot, Aurore [14 ]
机构：
[1] GHND Grp Hosp Nord Dauphine, Bourgoin Jallieu, France
[2] Grp Hosp Havre, Le Havre, France
[3] Janssen, Issy Les Moulineaux, France
[4] CH Chambery, Dept Hematol, Chambery, France
[5] Ctr Hosp St Quentin, St Quentin en Yvelines, France
[6] Hop St Vincent De Paul, Lille, France
[7] Ctr Hosp Univ Amiens Picardie, Serv Hematol, Amiens, France
[8] Hop Cote Nacre, Caen, France
[9] Hop Cochin, AP HP, Hematol Clin, Paris, France
[10] St Louis Hosp, Paris, France
[11] Janssen Cilag Spain, Madrid, Spain
[12] IFM, Paris, France
[13] CHU Toulouse Rangueil, Dept Nephrol & Transplantat, Toulouse, France
[14] Univ Toulouse, CHU Toulouse, IUCT O, UPS,Serv Hematol, Toulouse, France
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-180660
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Estimating direct costs of care for patients with relapsed or refractory multiple myeloma in french hospitals
    Armoiry, X.
    Fagnani, F.
    Benboubker, L.
    Facon, T.
    Fermand, J.
    Hulin, C.
    Moreau, P.
    Aulagner, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] COST OF CARE COMPARISON OF ELRANATAMAB-BCMM AND TECLISTAMAB-CQYV IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Shah, B.
    Sandin, R.
    Liu, Y.
    Hu, Y.
    Schepart, A.
    Hughes, D.
    Hart, J.
    Hlavacek, P.
    VALUE IN HEALTH, 2024, 27 (06) : S59 - S59
  • [43] Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study
    Cortes-Selva, Diana
    Perova, Tatiana
    Skerget, Sheri
    Vishwamitra, Deeksha
    Stein, Sarah
    Boominathan, Rengasamy
    Lau, Onsay
    Calara-Nielsen, Karl
    Davis, Cuc
    Patel, Jaymala
    Banerjee, Arnob
    Stephenson, Tara
    Uhlar, Clarissa
    Kobos, Rachel
    Goldberg, Jenna
    Pei, Lixia
    Trancucci, Danielle
    Girgis, Suzette
    Lin, Shun Xin Wang
    Wu, Liviawati S.
    Moreau, Philippe
    Usmani, Saad Z.
    Bahlis, Nizar J.
    van de Donk, Niels W. C. J.
    Verona, Raluca I.
    BLOOD, 2024, 144 (06) : 615 - 628
  • [44] Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study
    Nooka, Ajay K.
    Rodriguez, Cesar
    Mateos, Maria Victoria
    Manier, Salomon
    Chastain, Katherine
    Banerjee, Arnob
    Kobos, Rachel
    Qi, Keqin
    Verona, Raluca
    Doyle, Margaret
    Martin, Thomas G.
    van de Donk, Niels W. C. J.
    CANCER, 2024, 130 (06) : 886 - 900
  • [45] Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
    Girgis, Suzette
    Xin, Shun
    Lin, Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi
    Russell, Jeffery Scott
    Smit, Jennifer
    Goldberg, Jenna D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
    Hultcrantz, Malin
    Orozco, Jennifer
    Peterson, Tim J.
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Lu, Sydney X.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Maclachlan, Kylee H.
    Chung, David J.
    Landau, Heather J.
    Shah, Gunjan L.
    Lahoud, Oscar B.
    Scordo, Michael
    Landgren, Ola
    Giralt, Sergio
    Lesokhin, Alexander
    BLOOD, 2021, 138
  • [47] Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience
    Natsue Igarashi
    Takaaki Chou
    Takayuki Hirose
    Yousuke Imai
    Takuro Ishiguro
    International Journal of Hematology, 2010, 92 : 518 - 523
  • [48] Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A "real world" experience
    Fucci, Ludovica
    Gensini, Lorenzo
    Coppetelli, Ugo
    La Barbera, Elettra Ortu
    Gentile, Martina
    Fiori, Luciano
    Perrone, Salvatore
    Cimino, Giuseppe
    LEUKEMIA RESEARCH REPORTS, 2022, 17
  • [49] Bortezomib and dexamethasone for Japanese patients with relapsed and refractory multiple myeloma: a single center experience
    Igarashi, Natsue
    Chou, Takaaki
    Hirose, Takayuki
    Imai, Yousuke
    Ishiguro, Takuro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (03) : 518 - 523
  • [50] LENALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Okada, K.
    Okamoto, Y.
    Tsukamoto, T.
    Sugiura, H.
    Matsui, H.
    Ueda, T.
    Jo, T.
    Onishi, T.
    Kunitomi, A.
    Ueda, Y.
    ANNALS OF ONCOLOGY, 2013, 24
12345